- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Claribid, Clarinova, Cloff, Klacid, Bioclar, Crixan, Clarigard, Synclar
Synonyms :
Clarithromycin
Class :
Antibiotics and macrolide
Dosage forms & Strengths
Suspension Reconstituted, Oral:
125 mg/55ml
250 mg/5ml
Tablet, Oral:
250 mg
500 mg
Tablet extended release, Oral:
500 mg
group A Streptococcal (GAS) infections
Indicated for Streptococcal pharyngitis:
250 mg oral tablet immediate release twice a day for 14 days
Note: treatment should be initiated within 21 days of cough onset
500 mg oral tablet immediate release twice a day for 7 days
500 mg oral tablet immediate release twice a day for a minimum of 5 days
Acute symptomatic:
500 mg oral tablet immediate release twice a day for 14 days
500 mg oral tablet immediate release twice a day for 7 to 14 days
Note: Not advised for macrolide-based resistance patients.
Respiratory tract procedure (dental or invasive):
500 mg oral tablet immediate release administered prior to 30 to 60 minutes before the procedure
chronic obstructive pulmonary disease (COPD)
Acute exacerbation:
500 mg oral tablet immediate release every 12 hours for 5 to 7 days
Note: Not recommended for with risk infection of Pseudomonas
Dosage forms & Strengths
Suspension Reconstituted, Oral:
125 mg/55ml
250 mg/5ml
Tablet, Oral:
250 mg
500 mg
Tablet extended release, Oral:
500 mg
General dosing: infants to adolescents: 7.5 mg/kg orally twice a day, maximum dose 500 mg/dose
Dose instructions based on weight:
15 to <25 kg: 250 mg orally twice a day
25 to <35 kg: 500 mg orally in the morning and evening
>35 kg: 500 mg orally twice a day
Infants to adolescents:
7.5 mg/kg orally immediate release twice a day for 14 days
Acute: 7.5 mg/kg oral immediate release twice a day
may enhance serum concentrations of CYP3A4 inducers
may enhance serum concentrations of CYP3A4 inducers
may enhance serum concentrations of CYP3A4 inducers
may enhance serum concentrations of CYP3A4 inducers
may enhance serum concentrations of CYP3A4 inducers
clarithromycin: they may enhance serum concentrations of CYP3A4 Inducers
clarithromycin: they may enhance serum concentrations of CYP3A4 Inducers
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
may increase serum concentrations of CYP3A4 Inducers
It may enhance QTc interval when combined with pentamidine
rifabutin: they may enhance serum concentrations of clarithromycin
It may enhance QTc interval when combined with perphenazine
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
It may enhance QTc interval when combined with lithium
clarithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clarithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clarithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clarithromycin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
when both drugs are combined, there may be a decreased excretion rate of vincristine
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a reduced metabolism of erlotinib
the effect of clarithromycin is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, both increase the QTC interval
clarithromycin increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of clarithromycin
clarithromycin increases the effect of gilteritinib by altering the intestinal/renal CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increase in the QTC interval
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the serum concentration
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
glycopyrrolate inhaled and formoterol
may increase the QTc interval when combined
OATP1B1/1B3 inhibitors increase the concentration of asunapravir in the serum
OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum
OATP1B1/1B3 inhibitors increase the concentration of elbasvir and grazoprevir in the serum
OATP1B1/1B3 inhibitors increase the concentration of active metabolites of revefenacin in the serum
OATP1B1/1B3 inhibitors increase the concentration of taurursodiol in the serum
OATP1B1/1B3 inhibitors increase the concentration of voxilaprevir in the serum
may diminish the metabolism of clarithromycin
may increase the QTc prolonging effect of QT-prolonging agents
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of asunaprevir in the serum
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of elbasvir and grazoprevir in the serum
it increases the concentration of OATP1B1/1B3 substrates in the serum
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
It may intensify the hypoglycemic effect of sulfonylureas
It may intensify the hypoglycemic effect of sulfonylureas
It may intensify the hypoglycemic effect of sulfonylureas
It may intensify the hypoglycemic effect of sulfonylureas
It may intensify the hypoglycemic effect of sulfonylureas
It may enhance toxicity when combined with cholic acid by diminishing the elimination
it may enhance the risk of QTc prolongation when combined with amifampridine
It may enhance the levels when combined with tamsulosin by affecting CYP3A4 metabolism
when ajmaline is used together with clarithromycin, the risk or seriousness of QTc prolongation is enhanced
piperacillin decreases the effectiveness of clarithromycin by antagonism.
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
clarithromycin has a synergistic effect over brentuximab vedotin, by showing altered intestinal/hepatic CYP3A4 enzyme metabolism
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
QTc interval is increased both by lenvatinib and clarithromycin
may enhance the level and effect of docetaxel by affecting CYP3A4
when both drugs are combined, there may be an increased risk of adverse effects
it increases the QTc-prolonging effect of pazopanib
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
it may increase the toxicity of each other
may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates
eltrombopag increases the concentration of OATP1B1/1B3 substrates in the serum
OATP1B1/1B3 inhibitors increase the concentration of brincidofovir in the serum
OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum
may increase the serum concentration of OAT1/3 substrates
may increase the serum concentration of cabergoline
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
When bacampicillin combines with clarithromycin, the effect and action of drug decreases by synergism or antagonism.
The drug effectiveness of both may be decreased by synergism/antagonism.
clarithromycin, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism
Frequency defined:
>10%
Nausea (11%)
Fever (13%)
1%-10%:
Pruritis (5%)
Skin rash (2%)
Urticaria (5%)
Decreased serum bicarbonate (2%)
Metabolic acidosis (2%)
Abdominal distention (2%)
Diarrhea (7%)
Vomiting (7%)
Anemia (2%)
Neutropenia (2%)
Postmarketing:
Hepatotoxicity
Anaphylaxis
Pregnancy consideration: Clarithromycin can cross the placenta.
Lactation: Clarithromycin may be present in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: Clarithromycin
Pronounced: Cla-ri-thro-mi-sin
Why do we use clarithromycin?
Clarithromycin is a macrolide antibiotic. It is used to treat or prevent bacterial infections as H.pylori and mycobacterial infections.
